UPDATE: Brean Murray Carret Upgrades Vivus to Hold

According to Brean Murray Carret, Vivus

is upgraded to Hold. Brean Murray Carret said that the Qnexa AdComm panel voted 20 to 2 to approve the drug, and such overwhelming support for post marketing safety trials rather than further Phase 3 safety trials leads us to believe that the FDA will probably grant approval in April. “Our rating, therefore, has been upgraded to Hold, and VVUS has been removed from our Near-Term Conviction Focus list.” Vivus closed yesterday at $10.55.